Cohance Lifesciences Q1 FY27 Results

Consolidated Revenue: ₹422.26 crore
Consolidated Net Loss: ₹45.19 crore

Reader Takeaway: Revenue down, loss up; company expects H2 FY27 recovery amid strategic integration.

What just happened

Cohance Lifesciences commenced FY27 with a challenging first quarter. The company reported a consolidated revenue of ₹422.26 crore, marking a 23.1% year-on-year decrease from ₹549.31 crore in Q1 FY26. This led to a consolidated net loss of ₹45.19 crore, a reversal from the ₹46.40 crore profit recorded in the same period last year.

Why this matters

This marks a significant downturn for the company, impacting profitability in the first quarter of the fiscal year. Investors will be closely watching management's guidance for a turnaround, especially given the lumpy nature of the contract development and manufacturing organization (CDMO) business. The focus will be on revenue recovery in the latter half of the fiscal year and the successful integration of its subsidiaries.

The backstory

In the previous fiscal year, Q1 FY26 saw Cohance Lifesciences post a healthy profit. However, the current results reflect headwinds impacting the Pharma CDMO segment and shipment phasing. Management has described Q1 FY27 as a "bottoming out" period, signaling expectations for sequential improvements in subsequent quarters.

What changes now

Cohance Lifesciences is undergoing a strategic reorganization of its subsidiary, Sapala Organics, aiming for full ownership over the next few fiscal years to unify its nucleic acid business. Operationally, the company is focused on securing repeat business for its NJ Bio operations in the US and managing customer shipment schedules for its CDMO clients.

Risks to watch

Potential risks include the inherent volatility in the CDMO business due to shipment phasing, which can lead to fluctuating quarterly performance. Negative operating leverage and costs associated with subsidiary consolidation have also impacted margins. Contractual revenue risks exist for NJ Bio operations in the US.

Peer comparison

While specific peer results for the same quarter are not detailed in the filing, the CDMO sector generally faces pressures from global supply chain dynamics and client-specific project timelines. Companies in this space often manage lumpy revenue streams.

Context metrics (time-bound)

As of 30 June 2026, Cohance Lifesciences maintained a healthy net cash position of ₹251.2 crore. Two recently commercialized molecules are slated for delivery in upcoming quarters, and a significant restocking order for a commercial molecule has been secured, providing visibility for later in the fiscal year.

What to track next

Investors should monitor sequential revenue growth from Q2 FY27 onwards, the anticipated return to year-on-year growth in the second half of FY27, the progress in integrating Sapala Organics, and the operational improvements at NJ Bio. The company's sustainability ratings and emission reduction targets are also positive indicators.